Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Turkey Slashes Prices Yet Again, Pharmas Prepare For Worst Case Scenario

This article was originally published in PharmAsia News

Executive Summary

A third round of price cuts and substantial currency depreciation has manufacturers questioning investment in Turkey.

You may also be interested in...



GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)

In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In Q3, earnings in emerging markets were slightly down for GlaxoSmithKline PLC, Novo Nordisk A/S, and Eli Lilly & Co, mostly due to increased pricing pressure as well as increased competition in the diabetes market, with local players rapidly gaining market share..

Turkey Again Slashes Drug Prices; Manufacturers And Pharmacists Cry Foul

The Turkish Social Security Institution or SGK hiked institutional pharmaceutical discounts with a new regulation in December 2010, imposing an additional 9.5% price cut to its reference pricing system

Chinese-Language Podcast: 聊聊七月生物制药热门话题

Join our China-based content team for this latest Chinese-language podcast episode discussing selected hot topics impacting the biopharma industry in China, including a homegrown COVID-19 antiviral approval, ADC deals and cross-strait tensions and their impact on the biotech sector. 

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC076733

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel